CALGARY, Alberta, Jan. 31, 2022 XORTX Therapeutics Inc. , a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to. | January 31, 2022
XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
XORTX Therapeutics Inc.: XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection
CALGARY, AB / ACCESSWIRE / March 8, 2021
/ XORTX Therapeutics Inc.
XORTX or the
Company ) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late-stage clinical programs, is pleased to announce the filing of a new provisional patent application entitled Compositions and Methods for Enhancing Anti-Viral Therapies . This provisional patent was filed with the US Patent Office on Friday, March 5, 2021.
In addition, studies of Coronavirus infections show that SARS and MERS and specifically COVID-19 can be frequently accompanied by pneumonia, acute kidney injury, proteinuria and hematuria